We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




DNA Blood Test Evaluated for Colorectal Cancer Detection

By LabMedica International staff writers
Posted on 11 Jun 2014
Tumor-derived aberrant DNA can be detectable in blood and blood tests have the potential to improve screening for colorectal cancer.

A new blood test for bowel cancer based on two genes that are frequently hyper-methylated in colorectal adenoma and cancer (CRC) tissues, has been assessed for accuracy.

Scientists at Flinders University (Adelaide, SA, Australia) working with their Dutch colleagues enrolled 2,187 volunteers with a mean age of 62 years, 52% of which were male. More...
The patients were scheduled for colonoscopy for any reason, or for resection of colonic neoplasia, and were included if they provided sufficient plasma. The test was run successfully on 2,139 plasma specimens including 30 sample pairs taken pre- and post-surgical removal of neoplastic lesions.

Circulating cell-free DNA was extracted from plasma samples and bisulphite converted. Levels of recovered DNA and methylated Branched Chain Amino-Acid Transaminase 1, Cytosolic (BCAT1) and IKAROS Family Zinc Finger 1 (IKZF1) DNA were simultaneously determined using multiplexed quantitative polymerase chain reactions (qPCR) (Clinical Genomics; Sydney, NSW, Australia). A plasma sample was defined as positive if amplified target sequence signal above background fluorescence was present in any of three replicates in the BCAT1 or IKZF1 qPCR assay. Sensitivity and specificity for neoplasia were estimated as the primary outcome measures.

The two-gene blood test, BCAT1 and/or IKZF1 positive, successfully identified 85/130 (65.4%) of CRC cases. The successful detection rate increased to 73% for cancers that are Stage II or higher. The 12 BCAT1/IKZF1 methylation-positive CRC subjects with paired pre- and post-surgery plasma showed reduction in methylation signal after surgery, with complete disappearance of signal in 10 subjects. The presence of cancer-derived methylated DNA markers in plasma correlated with depth of tumor invasion and given the high rate of marker disappearance after cancer resection, the panel might also be useful to monitor tumor recurrence.

Graeme P. Young, MD, a professor of Gastroenterology and lead author of the study said, “A blood test is likely to overcome some of the barriers to screening with fecal tests. It might prove to be acceptable to those failing to participate in screening using established methods, which at the moment are primarily based around fecal tests.” The study was published on April 12, 2014, in the journal Gastrointestinal Endoscopy.

Related Links:

Flinders University 
Clinical Genomics



Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
Automated Clinical Chemistry Analyzer
Envoy 500+
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The approach supports myocardial infarction diagnosis in resource-limited settings by reducing delays between clinical suspicion and biochemical confirmation (Image Credit: Adobe Stock)

Portable Troponin Assay Brings Heart Attack Diagnosis Closer to Patients

Timely confirmation of myocardial infarction often depends on laboratory testing that may not be immediately available at the point of care. This gap between clinical suspicion and definitive evidence... Read more

Microbiology

view channel
Image: An innovative countywide program in Taiwan combines risk-based screening with decentralized community care to improve hepatitis C detection and treatment (Image Credit: iStock)

Precision Screening Helps Close Hepatitis C Diagnosis and Treatment Gaps

Hepatitis C remains a leading cause of cirrhosis and liver cancer, yet many infections go undiagnosed or untreated because health systems fail to reach those at greatest risk. Although highly effective... Read more

Pathology

view channel
Image: Through the PCCP, Proscia gains a more efficient pathway to expand Concentriq AP-Dx interoperability while maintaining regulatory oversight (Photo courtesy of Proscia)

FDA-Cleared Digital Pathology Platform Expands Interoperability for Primary Diagnosis

Rising cancer incidence is colliding with a shrinking pathologist workforce, intensifying pressure on diagnostic turnaround times in clinical laboratories. Many labs are adopting digital pathology to manage... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.